211 related articles for article (PubMed ID: 10733489)
21. Splenectomy in patients with myeloproliferative neoplasms: efficacy, complications and impact on survival and transformation.
Santos FP; Tam CS; Kantarjian H; Cortes J; Thomas D; Pollock R; Verstovsek S
Leuk Lymphoma; 2014 Jan; 55(1):121-7. PubMed ID: 23573823
[TBL] [Abstract][Full Text] [Related]
22. Portal hypertension complicating myelofibrosis: reversal following splenectomy.
Lukie BE; Card RT
Can Med Assoc J; 1977 Oct; 117(7):771-2. PubMed ID: 907949
[TBL] [Abstract][Full Text] [Related]
23. Splenectomy in myeloid metaplasia.
Silverstein MN; ReMine WH
Blood; 1979 Mar; 53(3):515-8. PubMed ID: 760865
[TBL] [Abstract][Full Text] [Related]
24. Splenic irradiation for symptomatic splenomegaly associated with myelofibrosis with myeloid metaplasia.
Elliott MA; Chen MG; Silverstein MN; Tefferi A
Br J Haematol; 1998 Nov; 103(2):505-11. PubMed ID: 9827926
[TBL] [Abstract][Full Text] [Related]
25. [Role of splenectomy in the treatment of myelofibrosis].
Melikian AL; Kolosova LIu; Sokolova MA; Kovrigina AM; Silaev MA; Giliazitdinova EA; Gemdzhian ÉG; Karagiulian SR
Ter Arkh; 2013; 85(8):69-76. PubMed ID: 24137967
[TBL] [Abstract][Full Text] [Related]
26. Myelofibrosis with myeloid metaplasia: clinical and haematological parameters predicting survival in a series of 133 patients.
Visani G; Finelli C; Castelli U; Petti MC; Ricci P; Vianelli N; Gianni L; Zuffa E; Aloe Spiriti MA; Latagliata R
Br J Haematol; 1990 May; 75(1):4-9. PubMed ID: 2375922
[TBL] [Abstract][Full Text] [Related]
27. Splenectomy for massive splenomegaly: long-term results and risks for mortality.
Taner T; Nagorney DM; Tefferi A; Habermann TM; Harmsen WS; Slettedahl SW; Donohue JH
Ann Surg; 2013 Dec; 258(6):1034-9. PubMed ID: 23222031
[TBL] [Abstract][Full Text] [Related]
28. The natural history of agnogenic myeloid metaplasia (AMM) and a critical evaluation of its relationship with the myeloproliferative syndrome.
Ward HP; Block MH
Medicine (Baltimore); 1971 Sep; 50(5):357-420. PubMed ID: 4940717
[No Abstract] [Full Text] [Related]
29. Splenectomy for agnogenic myeloid metaplasia.
Coon WW; Liepman MK
Surg Gynecol Obstet; 1982 Apr; 154(4):561-3. PubMed ID: 7064091
[TBL] [Abstract][Full Text] [Related]
30. Subtotal splenectomy for treatment of patients with myelofibrosis and myeloid metaplasia.
Petroianu A
Int Surg; 1996; 81(2):177-9. PubMed ID: 8912088
[TBL] [Abstract][Full Text] [Related]
31. [Splenectomy in osteomyelofibrosis. Indications and outcome].
Böhner H; Rötzscher VM; Tirier C; Heit W; Greiner J
Chirurg; 1996 Oct; 67(10):1016-9. PubMed ID: 9011420
[TBL] [Abstract][Full Text] [Related]
32. Splenectomy in patients with chronic myelomonocytic leukemia: Indications, histopathological findings and clinical outcomes in a single institutional series of thirty-nine patients.
Pophali P; Horna P; Lasho TL; Finke CM; Ketterling RP; Gangat N; Nagorney D; Tefferi A; Patnaik MM
Am J Hematol; 2018 Nov; 93(11):1347-1357. PubMed ID: 30105755
[TBL] [Abstract][Full Text] [Related]
33. Clinical correlates of splenic histopathology and splenic karyotype in myelofibrosis with myeloid metaplasia.
Mesa RA; Li CY; Schroeder G; Tefferi A
Blood; 2001 Jun; 97(11):3665-7. PubMed ID: 11369668
[TBL] [Abstract][Full Text] [Related]
34. Risk factors and a prognostic model for postsplenectomy survival in myelofibrosis.
Tefferi A; Mudireddy M; Gangat N; Hanson CA; Ketterling RP; Pardanani A; Nagorney DM
Am J Hematol; 2017 Nov; 92(11):1187-1192. PubMed ID: 28782256
[TBL] [Abstract][Full Text] [Related]
35. Splenectomy in the accelerated or blastic phase of chronic myelogenous leukemia: a single-institution, 25-year experience.
Bouvet M; Babiera GV; Termuhlen PM; Hester JP; Kantarjian HM; Pollock RE
Surgery; 1997 Jul; 122(1):20-5. PubMed ID: 9225910
[TBL] [Abstract][Full Text] [Related]
36. [Myelofibrosis with myeloid metaplasia. A study of 24 consecutive patients].
Bettini R; Redaelli S; Marzetta K; Maino C; Sala D; Saccà V; Gorini M
Recenti Prog Med; 2004; 95(7-8):358-64. PubMed ID: 15303545
[TBL] [Abstract][Full Text] [Related]
37. Splenic irradiation in myelofibrosis with myeloid metaplasia: a review.
Elliott MA; Tefferi A
Blood Rev; 1999 Sep; 13(3):163-70. PubMed ID: 10527268
[TBL] [Abstract][Full Text] [Related]
38. Low-dose thalidomide ameliorates cytopenias and splenomegaly in myelofibrosis with myeloid metaplasia: a phase II trial.
Marchetti M; Barosi G; Balestri F; Viarengo G; Gentili S; Barulli S; Demory JL; Ilariucci F; Volpe A; Bordessoule D; Grossi A; Le Bousse-Kerdiles MC; Caenazzo A; Pecci A; Falcone A; Broccia G; Bendotti C; Bauduer F; Buccisano F; Dupriez B
J Clin Oncol; 2004 Feb; 22(3):424-31. PubMed ID: 14752066
[TBL] [Abstract][Full Text] [Related]
39. Prognostic factors and current practice in treatment of myelofibrosis with myeloid metaplasia: an update anno 2000.
Cervantes F
Pathol Biol (Paris); 2001 Mar; 49(2):148-52. PubMed ID: 11317960
[TBL] [Abstract][Full Text] [Related]
40. Myelofibrosis and rapid thrombocytolysis. A case report.
Kutti J; Bergström AL; Ridell B
Acta Med Scand; 1977; 201(3):249-55. PubMed ID: 848365
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
